PRN 1008

Drug Profile

PRN 1008

Alternative Names: PRN-1008

Latest Information Update: 14 Nov 2016

Price : $50

At a glance

  • Originator Principia Biopharma
  • Class Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pemphigus vulgaris
  • Phase I Autoimmune disorders

Most Recent Events

  • 28 Oct 2016 Principia Biopharma completes a phase I pharmacokinetics trial in Healthy volunteers in Australia (PO, Tablet) (ACTRN12616001557426)
  • 12 Sep 2016 Principia Biopharma initiates a phase I pharmacokinetics trial in Healthy volunteers in Australia (PO, Tablet) (ACTRN12616001557426)
  • 01 Feb 2016 Phase-II clinical trials in Pemphigus vulgaris in Australia (PO, Tablet) (NCT02704429)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top